Embecta Past Earnings Performance
Past criteria checks 0/6
Embecta's earnings have been declining at an average annual rate of -46.2%, while the Medical Equipment industry saw earnings growing at 2% annually. Revenues have been growing at an average rate of 1.3% per year.
Key information
-46.2%
Earnings growth rate
-66.5%
EPS growth rate
| Medical Equipment Industry Growth | 4.3% |
| Revenue growth rate | 1.3% |
| Return on equity | n/a |
| Net Margin | 6.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Embecta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,133 | 70 | 366 | 85 |
| 31 Dec 23 | 1,122 | 55 | 359 | 89 |
| 30 Sep 23 | 1,121 | 70 | 341 | 85 |
| 30 Jun 23 | 1,114 | 47 | 328 | 80 |
| 31 Mar 23 | 1,119 | 94 | 324 | 71 |
| 31 Dec 22 | 1,116 | 160 | 305 | 67 |
| 30 Sep 22 | 1,130 | 224 | 295 | 67 |
| 30 Jun 22 | 1,156 | 338 | 284 | 69 |
| 31 Mar 22 | 1,160 | 380 | 260 | 70 |
| 31 Dec 21 | 1,169 | 408 | 249 | 66 |
| 30 Sep 21 | 1,165 | 415 | 240 | 63 |
| 30 Sep 20 | 1,086 | 428 | 215 | 61 |
| 30 Sep 19 | 1,109 | 432 | 222 | 62 |
Quality Earnings: JX7 has a large one-off loss of $26.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: JX7's current net profit margins (6.2%) are lower than last year (8.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JX7's earnings have declined by 46.2% per year over the past 5 years.
Accelerating Growth: JX7's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: JX7 had negative earnings growth (-25.6%) over the past year, making it difficult to compare to the Medical Equipment industry average (-2.8%).
Return on Equity
High ROE: JX7's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.